GTC Biotherapeutics pulls in $10M from shareholder

By Mass High Tech staff

Video Gallery

MHT's Julie Donnelly: Life science startups finding investments

MHT's Marc Songini: Technology to keep seniors healthy

MHT's Marc Songini: Mass. bio firms prep for lifting of stem cell ban

OncoPep licenses cancer vaccine, moves to add $500K to Series A [February 13, 2012]

Spin Transfer whips up $36M in first round [February 13, 2012]

Oxford Immunotec taps Altieri as CFO [February 13, 2012]

SeraCare selling to Linden for $82M [February 13, 2012]

GTC Biotherapeutics Inc., which has struggled financially in the last several months, has received $10 million in funding from strategic shareholder LFB Biotechnologies, a France-based drug maker.

The funding stems from LFB’s exercise of its option, outlined in July, to purchase $12.8 million in convertible preferred stock, amounting to $6.4 million in cash for GTC. The Framingham-based biotechnology firm also netted an additional $3.6 million from LFB’s additional purchase on Friday of 3.4 million shares of common stock.

The funding will aid GTC, which received its third delisting notice from the Listing Qualifications Staff of the Nasdaq Stock Market in September.

As part of a long-standing funding arrangement with LFB, GTC announced last month the resignations or four existing directors — Robert Baldridge, Kenneth Bauer, Mary Ann Gray and Marvin Miller — and the immediate replacements on the GTC board with William Heiden and LFB employees Evelyne Nguyen, Bertrand Merot and Jean-François Prost.

GTC (Nasdaq: GTCB) develops therapeutic proteins produced through transgenic animal technology. Its ATryn antithrombin is approved for use in the United States and Europe.

Comments

If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.